ArticleCancer medicine2025
End-Of-Life Outcomes and Healthcare Utilization for Patients With Hepatocellular Carcinoma Who Received Immune Checkpoint Inhibition.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
introductionImmune checkpoint inhibitors (ICI) have revolutionized treatment for advanced hepatocellular carcinoma (HCC). However, end-of-life (EOL) outcomes and healthcare utilization patterns prior to death for patients who receive ICI compared to non-ICI as their last therapy are unknown.
methodsPatients with advanced HCC evaluated from January 1, 2020, and who died by March 29, 2024, were included for analysis. Primary EOL outcomes include: advance directives, goals of care conversations, location of death, palliative care referral, hospice referral, and hospice duration. Secondary healthcare utilization outcomes include systemic therapy receipt, emergency department visits, hospitalizations, and intensive care unit admissions within 14, 30, and 90 days of death. Outcomes were stratified by ICI or non-ICI as the last therapy received, and p values were derived using Pearson's chi-square test for equality of proportions.
resultsWe identified 71 patients for our retrospective cohort: mean age 64.1 years; 70.8% male; Child Pugh (CP) status at last treatment: 51.1% CPA, 40.0% CPB, 8.9% CPC. No differences in EOL outcomes were detected between groups; median days enrolled in hospice did not differ (24.5 days [non-ICI] vs. 10 days [ICI]; p = 0.39). Yet, a higher proportion of patients who received ICI as the last therapy had increased healthcare utilization across secondary outcomes.
conclusionsPatients with advanced HCC receiving ICI as their last treatment before death, compared to those receiving non-ICI, had similar EOL outcomes but higher healthcare utilization. Further investigation into risk stratification to predict high healthcare utilizers could guide decision-making around the ongoing use of ICI near the EOL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.